Go to the list of all blogs
Allana's Avatar
published in Blogs
Nov 20, 2026
TickeronGET DAILY SIGNALS
MacroGenics (MGNX) Stock Falls -44% in 30 Days Despite Positive Clinical Data

MacroGenics (MGNX) Stock Falls -44% in 30 Days Despite Positive Clinical Data

Key Takeaways

  • MacroGenics shares fell roughly 44% over the past 30 days, declining from about $3.59 to near $2.00 as of the latest session.
  • The steepest decline occurred on October 23, 2026, when the stock dropped roughly 38% in a single session despite the company reporting positive interim Phase 1 data for its MGC026 ADC program.
  • Follow-up positive interim Phase 2 LINNET data for lorigerlimab in late October did not reverse the downward momentum.
  • Over the last quarter, the stock has declined approximately 51% from the $4 range, extending a pullback that began in September.
  • MacroGenics reported a strengthened balance sheet following its manufacturing divestiture, with pro forma cash of about $327 million and a projected runway through 2028.
  • Broader risk-off pressure on cash-burning, development-stage biotechs contributed to sentiment throughout the period.
  • For additional detail on Price Targets, Earnings, and Forecast, explore the dedicated MacroGenics pages for deeper analytics.
  • Explore Trending AI Robots to see which AI-driven trading strategies are currently gaining traction across the market.

MacroGenics (MGNX) Company Background and Pipeline Focus

MacroGenics, Inc. is a clinical-stage biopharmaceutical company headquartered in Rockville, Maryland, that develops antibody-based therapies aimed at treating cancer. Its approach relies on proprietary platforms such as the DART and TRIDENT bispecific technologies along with topoisomerase I inhibitor-based antibody-drug conjugate programs.

Key candidates in the pipeline include lorigerlimab, a PD-1 x CTLA-4 bispecific DART molecule, and MGC026, a B7-H3-directed ADC. The company also maintains partnerships that provide milestone and royalty opportunities, including work with Gilead Sciences, Sanofi on TZIELD, and Incyte on ZYNYZ. Clinical readouts remain central to how investors assess the shares.

MacroGenics (MGNX) Stock Performance Over the Past 30 Days and Quarter

Shares of MGNX have declined about 44% in the last 30 days, moving from a closing price near $3.59 in late October to roughly $2.00 in the most recent session. A single-day drop of approximately 38% on October 23, 2026, on elevated volume stood out as the sharpest move.

The quarterly picture shows an even larger decline. Three months earlier the stock traded near $4.07, so the shares have lost roughly 51% of their value over that span. After reaching the low-$4 range in August and early September, the stock entered a sustained pullback that intensified after the October data releases.

Factors Behind the Recent 30-Day Move in MGNX

The standout event was the October 23, 2026, release of positive interim Phase 1 results for MGC026 at the ESMO 2026 Congress. The data indicated a 27% best overall response rate in heavily pretreated SCCHN patients, along with a manageable safety profile and no reported cases of interstitial lung disease or ocular toxicity.

Even with the encouraging framing, the stock fell about 38% that day. While company disclosures did not fully detail the driver, the reaction fits a pattern seen with clinical-stage biotechs where investors focus on durability, competition, and potential dilution. A broader risk-off tone across cash-burning development-stage names added pressure. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Later in October the company released positive interim Phase 2 LINNET results for lorigerlimab in advanced clear cell gynecologic cancer, showing a confirmed objective response rate of 25% and a disease control rate of 44%. Third-quarter results and the addition of two new independent directors in mid-November followed, yet none of these updates halted the downward trend.

Drivers of the Quarterly Decline and Corporate Changes

Over the quarter the stock moved from the $4 range down toward $2, representing a decline of roughly 51%. Shares peaked in the low-$4s in early September before a steady descent that reflected caution ahead of the ESMO presentations and wider weakness among small-cap biotechs.

Corporate restructuring also featured in the period. MacroGenics completed the sale of its GMP manufacturing operations to Bora Pharmaceuticals for $122.5 million and shifted to a fully outsourced model with a smaller workforce. This left the company with pro forma cash of about $327 million and an extended runway through 2028. While the improved financial position added flexibility, the clinical data-driven repricing remained the dominant influence on performance.

Key Pipeline Milestones and Market Factors to Monitor

Looking forward, attention will likely center on further clinical updates. The company expects to finish enrolling clear cell gynecologic cancer patients at the lower lorigerlimab dose by the end of 2026, with updated results expected in the first half of 2027. Additional data from the MGC026 program and progress on MGC030, which dosed its first patient in October, will also draw scrutiny.

Macroeconomic elements such as interest-rate expectations and financing conditions for development-stage biotechs continue to shape sentiment. Competitive shifts in the ADC and bispecific spaces, along with any partnership news involving Gilead, Sanofi, or Incyte, could matter as well. Monitoring earnings, guidance, and analyst revisions will provide further signals.

Integrating AI Tools Into Biotech Research

When analyzing volatile names like this one, I find it helpful to review automated strategies alongside fundamental work. Tickeron’s AI Trading Bots offer a straightforward way to compare algorithmic approaches across different timeframes and market conditions, which can complement traditional pipeline reviews without replacing them.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: MGNX

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


MGNX's Indicator enters downward trend

The Aroon Indicator for MGNX entered a downward trend on November 04, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 216 similar instances where the Aroon Indicator formed such a pattern. In 195 of the 216 cases the stock moved lower. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MGNX as a result. In 78 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.

The 50-day moving average for MGNX moved below the 200-day moving average on November 11, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MGNX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Moving Average Convergence Divergence (MACD) for MGNX just turned positive on November 10, 2026. Looking at past instances where MGNX's MACD turned positive, the stock continued to rise in 42 of 51 cases over the following month. The odds of a continued upward trend are 82%.

Following a +3.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where MGNX advanced for three days, in 228 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

MGNX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating steady price growth. MGNX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.462) is normal, around the industry mean (3.596). P/E Ratio (-10.591) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (10.770) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (1.477) is also within normal values, averaging (443.347).

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MGNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -9%. For the same Industry, the average monthly price growth was -16%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 111%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 84%. For the same stocks of the Industry, the average monthly volume growth was 101% and the average quarterly volume growth was 38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 68
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company, which engages in the discovery and development of monoclonal antibody-based therapeutics

Industry Biotechnology

Industry
Biotechnology
Address
9704 Medical Center Drive
Phone
+1 301 251-5172
Employees
293
Web
https://www.macrogenics.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.